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Alzheimer’s disease (AD) is a neurodegenerative disorder involving impaired cholinergic neurotrans-
mission and dysregulation of nicotinic acetylcholine receptors (nAChRs). Ly-6/neurotoxin (Lynx) proteins
have been shown to modulate cognition and neural plasticity by binding to nAChR subtypes and
modulating their function. Hence, changes in nAChR regulatory proteins such as Lynx proteins could
underlie the dysregulation of nAChRs in AD. Using Western blotting, we detected bands corresponding to
the Lynx proteins prostate stem cell antigen (PSCA) and Lypd6 in human cortex indicating that both
proteins are present in the human brain. We further showed that PSCA forms stable complexes with the
a4 nAChR subunit and decreases nicotine-induced extracellular-signal regulated kinase phosphorylation
in PC12 cells. In addition, we analyzed protein levels of PSCA and Lypd6 in postmortem tissue of medial
frontal gyrus from AD patients and found signiﬁcantly increased PSCA levels (approximately 70%). In
contrast, no changes in Lypd6 levels were detected. In concordance with our ﬁndings in AD patients,
PSCA levels were increased in the frontal cortex of triple transgenic mice with an AD-like pathology
harboring human transgenes that cause both age-dependent b-amyloidosis and tauopathy, whereas
Tg2576 mice, which display b-amyloidosis only, had unchanged PSCA levels compared to wild-type
animals. These ﬁndings identify PSCA as a nAChR-binding protein in the human brain that is affected
in AD, suggesting that PSCA-nAChR interactions may be involved in the cognitive dysfunction observed
in AD.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia
in the elderly individuals. Characteristics of AD consist of accumu-
lation of b-amyloid (Ab) plaques and neuroﬁbrillary tangles of
hyperphosphorylated tau proteins (Querfurth and LaFerla, 2010).
Another neuropathologic feature of AD is the selective degenera-
tion of cholinergic neurons in the basal forebrain, which is associ-
atedwith the cognitive decline in AD (reviewed in Auld et al., 2002).
The most abundant nicotinic acetylcholine receptors (nAChRs)
in the brain, a7 and a4b2, are involved in cognitive performance,
such as attention and memory function, as well as synapticgn and Pharmacology, Faculty
hagen, Universitetsparken 2,
.S. Thomsen).
ll rights reserved.plasticity (reviewed in Sarter et al., 2009; Thomsen et al., 2010).
Accordingly, they have been widely investigated for their involve-
ment in the pathology of AD. Genetic analyses have demonstrated
associations between single-nucleotide polymorphisms in the a7
nAChR gene and AD (Carson et al., 2008b) as well as the delusional
symptoms in AD (Carson et al., 2008a). Single-nucleotide poly-
morphisms in the genes of a4 (Dorszewska et al., 2005; Kawamata
and Shimohama, 2002) and b2 nAChR subunits (Cook et al., 2004;
Laumet et al., 2010) have also shown to be associated with AD.
Recent studies agree that a4b2 nAChR levels are decreased in AD.
Thus, reduced [3H]-nicotine binding was observed postmortem in
frontal cortex of AD patients (Marutle et al., 2013), and binding of
the a4b2 nAChR radioligand [18F]-2FA-85380, by the use of PET, was
decreased in several brain regions of AD patients and demonstrated
signiﬁcant correlations with both Ab levels in the medial prefrontal
cortex and cognitive performance of the AD patients (Okada et al.,
2013). In contrast, there is currently no consensus on whether a7
nAChR levels in the brain are changed in AD, because binding
Table 1
Clinicopathologic data of the human brain material
Diagnosis Age Gender pH PMD (h:min) Braak stage
Nondemented control 60 F 6.27 06:50 1
Nondemented control 60 F 6.80 07:30 1
Nondemented control 62 M 6.36 07:20 1
Nondemented control 78 M 6.52 <17:40 1
Nondemented control 87 M 7.11 08:00 1
Nondemented control 87 F 6.91 08:00 2
Nondemented control 97 F d 10:00 2
Nondemented control 90 F 6.54 06:10 3
Alzheimer’s disease 67 F 6.73 03:30 5
Alzheimer’s disease 58 M 6.29 05:15 6
Alzheimer’s disease 58 M 6.42 06:25 6
Alzheimer’s disease 59 M 6.26 05:05 6
Alzheimer’s disease 62 M 6.31 04:15 6
Alzheimer’s disease 62 F 6.53 04:25 6
Alzheimer’s disease 62 F 6.06 04:45 6
Key: F, female; M, male; PMD, postmortem delay.
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et al., 2001; Davies and Feisullin, 1981; Hellstrom-Lindahl et al.,
1999; Marutle et al., 2013).
Ab1e42 has been shown to bind both a7 and a4b2 nAChRs, the
former with picomolar afﬁnity, whereas its afﬁnity for a4b2 was
5000 times lower (Wang et al., 2000). Furthermore, Ab1e42 is able to
modulate the function of both a7 and a4b2 nAChRs with dose-
dependent effects (reviewed in Buckingham et al., 2009;
Jurgensen and Ferreira, 2010).
In addition to Ab1e42, several members of Ly-6/neurotoxins
(Lynx) protein superfamily have been shown to modulate the
function of nAChRs (reviewed in Miwa et al., 2011; Thomsen and
Mikkelsen, 2012). Therefore, alterations in a7 and a4b2 nAChRs
may be secondary to changes in Lynx protein levels.
The Lynx superfamily has structural similarities to snake venom
toxins such as a-bungarotoxin and are characterized by a “three-
ﬁngered” loop motif (Tsetlin, 1999). The Lynx proteins Lynx1 and
Lynx2 have been shown to form stable complexes with and nega-
tively regulate both a7 and a4b2 nAChRs (Ibanez-Tallon et al., 2002;
Miwaet al., 2006; Tekinayet al., 2009). In addition,micewithgenetic
deletions of Lynx1 or Lynx2 displayed increased associative learning
and elevated anxiety-like behavior, respectively (Miwa et al., 2006;
Tekinay et al., 2009). Moreover, it was recently shown that Lynx1
through a nAChR-dependent action had a crucial role in the loss of
synaptic plasticity observed in adult visual cortex (Morishita et al.,
2010). Furthermore, transgenic overexpression of the Lynx protein
Lypd6 in mice resulted in increased pre-pulse inhibition indicating
possible involvement in attention (Darvas et al., 2009). Thus, Lynx
proteins are suggested to be involved in cognitive function.
Prostate stem cell antigen (PSCA), another Lynx protein, was
found to suppress nicotine-induced Ca2þ inﬂux via activation of a7
nAChRs, when retrovirally expressed in dissociated avian ciliary
ganglion neurons (Hruska et al., 2009). In contrast, nicotine-
induced Ca2þ currents were enhanced in dissociated murine tri-
geminal ganglia neurons from transgenic mice overexpressing
Lypd6, suggesting that Lypd6 is a positive modulator of nAChR
function (Darvas et al., 2009).
Because nAChRs and Lynx proteins can bind directly to each
other to affect cognitive function and synaptic plasticity, it is
pertinent to examine the involvement of Lynx proteins in AD. The
purpose of this study was to (1) investigate PSCA and Lypd6 in the
human brain in relation to expression and complex formations with
nAChR subtypes; (2) examine the ability of PSCA to modulate a
nicotine-mediated response in PC12 cells; and (3) reveal whether
the levels of the two Lynx proteins were changed in AD in both
human AD patients and transgenic AD mouse models.
2. Methods
2.1. Human tissue
Temporal cortical tissue was obtained from anterior temporal
lobectomies in two patients (1 female, aged 30 years and 1 male,
aged 57 years) with medically intractable temporal lobe epilepsy
with hippocampal onset. Written informed consent was obtained
from both patients before surgery. The study was approved by the
Ethical Committee in the Capital Region of Denmark (H-2-2011-
104) and performed in accordance with the Declaration of Helsinki.
The tissue was dissected and immediately frozen on dry ice and
stored at80 C until use. The neuropathologic examinations of the
neocortex from both patients were normal.
Postmortem brain tissue from medial frontal gyrus of 7 AD
subjects and 8 nondemented (non-AD) control subjects (see
Table 1) were obtained from the Netherland’s Brain Bank, Amster-
dam, the Netherlands. Autopsies were performed on donors fromwhomwritten informed consent had been obtained either from the
donor or direct next of kin. All AD subjects were conﬁrmed by
standard clinical (Dubois et al., 2007; McKhann et al., 1984) and
neuropathologic (Braak and Braak, 1991, 1995) diagnosis criteria.
2.2. Animals
Triple transgenic mice (3Tg-AD), expressing mutant human
transgenes (human amyloid precursor protein [APP] 695 with the
Swedish double mutation K670N/M671L [hAPPSwe], tau P301L)
mutation, and the presenilin-1 mutant M146V knock-in construct
(Oddo et al., 2003), were studied in two different age groups: 6-
month-old mice (n ¼ 8) and 19- to 21-month-old mice (n ¼ 8)
with age-matched wild-type (WT) mice (Sv129/B6; n ¼ 7e8) as
controls. The mice were bred at the Medizinisch-Experimentelles
Zentrum at Leipzig University. At the day of experiment, the mice
were decapitated, frontal cortex and hippocampus dissected, and
the tissue was immediately frozen on dry ice and stored at 80 C
until use.
Twelve male Tg2576 mice expressing the hAPPSwe mutations
(Hsiao et al.,1996) and theirWT littermates (n¼ 15) bred on an inbred
129S6 background were obtained from Taconic (Ry, Denmark). At the
age of 9 months, in an unrelated set of experiments, the mice
received bilateral intracerebroventricular phosphate-buffered saline
(PBS) injections (Laursen et al., 2014) followed by electrophysiological
testing. Mice were euthanized at the age of 15 months, and one
hemisphere was dissected, snap frozen, and kept at 80 C until
further analysis. Frontal cortex was later separated from the frozen
sample and used for Western blot analyses as described in the
following.
Experiments with 3Tg-AD were approved by the Animal Care
and Use Committee of the University of Leipzig and local authorities
(Regierungspräsidium Leipzig; T40/13) and conformed to the Eu-
ropean Communities Council Directive (86/609/EEC). Experiments
with Tg2576 mice were approved by the Danish National Com-
mittee for Ethics in Animal Experimentation.
2.3. Tissue fractionation
To fraction tissue into membrane and soluble fractions, human
temporal cortical tissue from neurosurgery (150e170 mg, n ¼ 2)
was homogenized 2  30 seconds in Buffer1 (0.5 M NaCl, 50 mM
TriseHCl, 10 mM MgCl2, 2 mM ethylenediaminetetraacetic acid
(EDTA), 10 mL/mL protease inhibitor cocktail [Sigma-Aldrich,
Brøndby, Denmark], pH 7.3) using a PT1200C polytron blender
(Kinematica, Luzern, Switzerland) and centrifuged for 30 minutes
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(Airfuge, Copenhagen, Denmark). The supernatant containing the
soluble fraction was transferred to a new tube, and the pellet
containing the membrane fraction was washed twice in Buffer1,
resuspended by blending 2  30 seconds in Buffer2 (4 M urea,
50 mM TriseHCl, 1% SDS, 10 mL/mL protease inhibitor cocktail, pH
7.3), and sonicated 3  5 seconds on ice.
2.4. PSCA afﬁnity puriﬁcation
Recombinant human GST-tagged PSCA produced in Escherichia
coli (purchased fromMyBioSource Inc, San Diego, CA) and dissolved
to 0.7 mg/mL in PBS, pH 7.4 was coupled to PureProteome NHS
Flexibind magnetic beads (Millipore, Billerica, MA) in a ratio of
1:1.25 (vol/vol). In brief, beads were washed once in ice-cold 1 mM
HCl before addition of the PSCA solution. Subsequently, beads were
incubated overnight at 4 C in a rotator (15 rpm). Unbound PSCA
was removed, and the beads were resuspended and washed four
times in Quench buffer (100 mM Tris-HCl, 150 mM NaCl, pH 8.0)
followed by incubation for 1 hour at room temperature. A batch of
beads without PSCA in the PBS was processed in parallel as a
negative control. The beads were incubated in 0.1% bovine serum
albumin in PBS, pH 7.4, for 1 hour at 4 C before use.
The tissuewas lysed in 1mL lysis buffer (50mMTris, 50mMNaCl,
5mMEDTA, 5mMEGTA,10 mL/mLprotease inhibitor cocktail [Sigma-
Aldrich, pH 7.5]) using the PT1200C polytron blender for 20 seconds.
The lysatewas centrifuged for 30minutes at 160,000g at 20 Ce22 C
using the air-driven ultracentrifuge and the supernatant discarded.
The pellet was resuspended in 1 mL lysis buffer containing 2% Triton
X-100 by blending for 20 seconds and incubated for 2 hours at 4 C on
a rotor (15 rpm). Thereafter, the samplewascentrifugedasmentioned
previously, and the resulting supernatant (input)was used for afﬁnity
puriﬁcation. Total protein content was determined using the Pierce
660 nm Protein Assay (Thermo Scientiﬁc, Rockford, IL), and 1000 mg
proteinwas incubatedwith 50 mLmagnetic beads in a total volume of
1500 mL lysis buffer for 18e22 hours at 4 C in a rotator (15 rpm). A
sample of the homogenate after afﬁnity puriﬁcation was taken
(output). Subsequently, the beads were washed twice in 1 M NaCl,
8 mM Na2HPO4, 2 mM NaH2PO4, 0.5% Triton X-100, pH 7.5 and three
times in an identical buffer, where 1 M NaCl was substituted with
0.1 M NaCl, and thereafter, the samples were immediately processed
for Western blotting.
2.5. ERK phosphorylation and b2 nAChR expression in PC12 cells
PC12 cells weremaintained in 75 cm2 ﬂasks coatedwith 5 mg/mL
poly-L-lysine (Sigma-Aldrich), in Dulbecco modiﬁed Eagle medium
(DMEM, Gibco Life Technologies, NY) supplemented with 10% heat-
inactivated horse serum, 5% fetal bovine serum, 25 U/mL penicillin,
25 mg/mL streptomycin, 1 mM sodium pyruvate, and 2 mM gluta-
mine (complete culture medium) at 37 C in a humidiﬁed incubator
with 5% CO2. Cells were subcultured every 3e4 days by detachment
with 0.25% trypsin in EDTA solution (Gibco Life Technologies) and
reseeded at 15% conﬂuence.
For the extracellular-signal regulated kinase (ERK) phosphory-
lation assay, cells were seeded in 24-well plates at 12  104 cells/
cm2, in low serum medium (1% heat-inactivated horse serum, 0.5%
fetal bovine serum) 24 hours before the experiments, which started
by incubating cells for 10 minutes with recombinant human PSCA
protein (MyBiosource) in the concentrations (0.1, 1, and 10 mM)
diluted in DMEM, followed by stimulation with 25 mM nicotine
(Sigma-Aldrich) for 5 minutes. For the b2 nAChR expression assay,
PC12 cells were seeded in 96-well plates at 12  104 cells/cm2 on
the day of the experiment in complete culture medium. Subse-
quently, cells were stimulated for 24 hours with recombinanthuman PSCA protein (MyBiosource) in the concentrations (0.1, 1,
and 10 mM) diluted in DMEM. Thereafter, cells were immediately
lysed in 100 mL and 50 mL, respectively, ice-cold lysis buffer/well
(100 mM NaCl, 25 mM EDTA, 10 mM Tris, 4 mM Na3VO4, 1 mM NaF,
and 1% [vol/vol] Triton X-100, 1% [vol/vol] NP-40, 1 mL/mL protease
inhibitor cocktail [Sigma-Aldrich], pH 7.4). To ensure complete lysis,
lysates were then placed in 80 C for 15 minutes, thawed, and
sonicated for 5 seconds on ice. Lysates were stored at 80 C until
they were processed for Western blotting.
2.6. Small interfering RNA transfection and real-time quantitative
reverse transcription polymerase chain reaction
FlexiTube small interfering RNA (siRNA) (Qiagen, Limburg, the
Netherlands) against PSCA (TACAATCATCCTGTAATAAAT) and a
scrumbled negative control were diluted in DMEM (Gibco Life
Technologies) to a ﬁnal concentration of 50 nM. The transfection
reagent Lipofectamine 2000 (Life Technologies, Carlsbad, CA) was
diluted in opti-MEM (Life Technologies) and incubated for 5 mi-
nutes at room temperature according to the manufacturer’s in-
structions. siRNAs were mixed with the transfection reagent and
incubated further for 15 minutes at room temperature to allow the
formation of transfection complexes. Subsequently, 100 mL of
transfection complexes were added into each well of a 24-well
plate, and PC12 cells were seeded at 24  104 cells/cm2 in com-
plete culture medium without antibiotics. Cells were incubated at
37 C in a humidiﬁed incubator with 5% CO2. After 48 hours, the
medium was removed, the plate was placed on ice, and RNA was
immediately extracted using the RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions.
RNA samples were dissolved in RNase-free water, and RNA
content was quantiﬁed using a Nanodrop ND-1000 Spectropho-
tometer (Nanodrop Technologies, Wilmington, DE). Samples were
diluted with RNase-free water to equal RNA concentrations and
reverse transcribed into single-stranded complementary DNA
(cDNA)with the ImProm-II Reverse Transcription System (Promega,
Madison, WI) according to the manufacturer’s directions using
0.5 g/reaction oligo(dT)15 primers, 6 mM MgCl2, and 20 units of
RNase inhibitor. Real-time quantitative reverse transcription poly-
merase reactions (RT-qPCR) were performed in a total volume of
20 mL, containing 1 mL sample cDNA,1 Brilliant II SYBRGreen qPCR
Master Mix (Stratagene, La Jolla, CA), and 15 pmol each of the for-
ward and reverse primers (DNA Technology, Aarhus, Denmark). RT-
qPCR was performed on a Light Cycler 480 Real-Time PCR System
(Roche, Indianapolis, IN) with a 10-minute preincubation at 94 C
followed by 40 cycles of 30 seconds at 94 C, 45 seconds at 60 C,
and 90 seconds at 72 C. Primer pairs were validated by using
serially diluted cDNA to establish a standard curve and by con-
ﬁrming the existence of a single product on a gel at the correct
molecular weight. Quantiﬁcation of messenger RNA (mRNA)
expressionwas performed according to the comparative CT method
as described by (Schmittgen and Livak, 2008). For each sample, the
amount of target mRNA was normalized to the amount of GAPDH.
The sequence of the designedprimerswere as follows: PSCA, forward
50-GCCCTACCAGTTCTGATCAG-30, reverse 50-TCACACCCACCTAGCTTCAT-
3’; b2 nAChR, forward 50-ACGGTGTTCCTGCTGCTCATC-30, reverse
50-CACACTCTGGTCATCATCCTC-3’; and GAPDH, forward 50-CATCAA-
GAAGGTGGTGAAGCA-30, reverse 50-CTGTTGAAGTCACAGGAGACA-3’.
2.7. Tissue preparation for Western blotting
Human postmortem cortical tissuewas lysed in homogenization
buffer (50 mM Tris, 100 nM NaCl, 25 mM EDTA, 1% [vol/vol] Triton-
X, 1% [vol/vol] NP-40, 1 mL/mL protease inhibitor cocktail [Sigma-
Aldrich], pH 7.4). Mouse cortical tissue was lysed in lysis buffer
Fig. 1. Prostate stem cell antigen (PSCA) is soluble and co-puriﬁes with the a4 nAChR
subunit in human cortex. (A) The antiserum directed against PSCA recognizes the
human recombinant GST-tagged PSCA protein (total molecular weight 34.2 kDa) from
1 to 16 ng/well at the expected band size. Endogenous PSCA from mouse and human
cortical tissue (8 mg total protein/well) is detected at approximately 24 kDa, and the
amount in the cortical samples was compared with the known concentrations of re-
combinant PSCA protein. (B) Images of Western blot showing PSCA protein levels in
cortical tissue from human (protein concentration 4, 8, and 12 mg/well) and mouse (8,
15, and 30 mg/well) in the absence (peptide) and the presence of PSCA peptide
(þpeptide). (C) Representative images of Western blots showing PSCA and Lypd6
protein levels in soluble and membrane fractions of human temporal cortical tissue.
The membrane receptor proteins b2 nAChR and GluR2 are used as control. (D) Mag-
netic beads covalently coupled with PSCA recombinant protein were incubated with
cortical homogenates from human temporal cortex followed by detection of nAChR
subunits by Western blot. Homogenates before (input) and after afﬁnity puriﬁcation
(output) as well as the negative control (CTRL) were loaded.
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hibitor cocktail [Sigma-Aldrich], pH 7.4). All lysates were brieﬂy
sonicated 2  5 seconds and centrifuged at 1000g for 10 minutes at
4 C. The resultant supernatant was used for detection of proteins
using Western blotting as described in the following.
2.8. Western blotting
Total protein content was determined using the DC Protein
Assay Kit (BioRad, Hercules, CA), and the samples were diluted in
loading buffer (ﬁnal concentration: 60 mM Tris, 10% [vol/vol]
glycerol, 5% [vol/vol] mercaptoethanol, 2% [wt/vol] SDS, 0.025% [wt/
vol] bromophenol blue, pH 6.8), incubated for 5 minutes at 95 C,
and submitted to gel electrophoresis using AnykD gels (BioRad).
After blotting onto polyvinylidene diﬂuoride membranes (BioRad),
the membranes were washed in Tris-buffered saline with 0.1%
Tween 20 (TBS-T), and blocked in TBS containing 5% (wt/vol) dry
milk powder. Blots were incubated in primary antisera against PSCA
(1:1,000, #NB100-91938, Novus Biologicals, Cambridge, UK), Lypd6
(1:1,000, #ARP53451_P050, Aviva Systems Biology, San Diego, CA),
b2 nAChR subunit (1:1,000, kindly provided by Dr Cecilia Gotti,
previously characterized in Thomsen et al., 2014), GluR2 (1:200,
#MABN71, Millipore), a4 nAChR subunit (1:100, sc-5591, Santa Cruz
Biotechnology), a7 nAChR subunit (1:1000 #ab23832, Abcam,
Cambridge, UK), or actin (1:10,000, #A5060, Sigma-Aldrich) over-
night at 4 C. Subsequently, blots were washed in TBS-T 3 
10 minutes followed by 1 hour incubation at room temperature
with horseradish peroxidase-conjugated secondary antibodies
(1:2000, Dako, Glostrup, Denmark). After thoroughwashing in TBS-
T, blots were visualized by enhanced chemiluminescence reagents
(Western Lightning ECL Pro, Perkin Elmer, Waltham, MA) using a
Chemidoc XRS system with Quantity One software (BioRad). Data
were quantiﬁed by measuring mean optical densities of bands and
subtracting an adjacent background measurement.
Validation of PSCA antibody (1:1,000, Novus Biologicals) was
done with co-incubation with the PSCA peptide, which had been
used as immunogen (1:100, # NB100-91938PEP, Novus Biologicals).
To determine the amount of endogenous PSCA in cortex, cortical
samples from mouse and human cortex were loaded along with
samples with known concentrations of the recombinant PSCA (0.5,
1, 2, 4, 8, and 16 ng). A standard curve was created based on the
PSCA samples and used to determine the amount of PSCA in the
cortical samples.
2.9. Immunoﬂuorescence labeling
Age-matched 3Tg-AD and WT mice (n ¼ 8) were perfused
transcardially with phosphate-buffered 4% paraformaldehyde after
being euthanized with CO2. Dissected brains were immersed in
ﬁxative overnight, dehydrated, and cut with a freezing microtome
resulting in free-ﬂoating, 30-mm-thick coronal sections. Selected
sections containing the frontal cortex or the hippocampal forma-
tion were used for phospho-tau and Ab-immunolabeling according
to an earlier protocol with minor modiﬁcations (Härtig et al., 2014).
Tissues were incubated with a mixture of biotinylated mouse-anti-
Ab17e24 (4G8; Covance, Emeryville, CA; 1:400 in TBS with 5%
normal donkey serum) and rabbit-anti-phospho-tau205 (Invi-
trogen, Karlsruhe, Germany; 1:300) overnight. Subsequently, the
sections were rinsedwith TBS and incubated for 1 hour in amixture
of carbocyanine 2 (Cy2)-conjugated streptavidin and Cy3-tagged
donkey anti-rabbit IgG (both from Dianova, Hamburg, Germany;
20 mg/mL TBS containing 2% bovine serum albumin). After washing
with TBS, the sections were treated with Sudan Black B for 10 mi-
nutes (Schnell et al., 1999) and mounted onto glass slides. For data
illustration, images were taken from selected sections using a 510Meta confocal laser-scanning microscope (Zeiss, Jena, Germany)
and processed with CorelDraw and/or Photo-Paint version 12.0
(Corel Corp, Ottawa, Canada).
2.10. Statistical analyses
Data from PC12 cells were analyzed using one-way analysis of
variance (ANOVA) with Dunnett multiple comparisons test. Corre-
lation of age, postmortem delay, and pH with protein levels in
human subjects was done using Pearson correlation analysis. Two-
way ANOVA was applied to analyze effects of genotype and age in
3Tg-AD mice. Unpaired multiple t tests using the Holm-Sidak
method was used to compare groups. The statistical calculations
were performed using GraphPad Prism version 6 for Windows
(GraphPad Software, San Diego, CA). Data are presented as mean 
Fig. 2. Prostate stem cell antigen (PSCA) inhibits nicotine-induced ERK phosphorylation. (A) Preincubation with 10 mM recombinant human PSCA reduces nicotine-induced ERK
phosphorylation in PC12 cells. Values are presented as the ratio between phosphorylated and total ERK protein and normalized to the 25 mM nicotine group. (B) Representative
images of Western blots. (C) Protein levels of the b2 nAChR subunit are unchanged after 24 hours stimulation with PSCA in PC12 cells. (D) Representative images of Western blots.
Data are normalized to actin levels, and the vehicle group is set to 1. (E) Silencing PSCA messenger RNA (mRNA) expression in PC12 cells with PSCA small interfering RNA (siRNA) has
no effect on b2 nAChR mRNA levels. Data are normalized to GAPDH levels, and the control (CTRL) group is set to 1. **p < 0.01 indicates statistical difference in a one-way analysis of
variance with Dunnett multiple comparisons test (n ¼ 4e6). Vehicles are not included in the statistical test in A. ***p < 0.001 indicates statistical difference in an unpaired t test.
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tistically signiﬁcant.
3. Results
3.1. PSCA is a soluble protein that binds to a4 nAChR subunits in the
human cortex
The PSCA antiserum recognized recombinant human PSCA
protein in the concentration range of 1e16 ng/well at molecular
weight band of approximately 34 kDa (Fig. 1A). Recombinant PSCA
protein consisted of 75 amino acids (immunogen sequence posi-
tions 21e95) with a calculated molecular weight of 8.2 kDa. How-
ever, this protein was GST-tagged (approximately 26 kDa) resulting
in a total molecular weight of approximately 34 kDa, which
correlated with the molecular weight of the identiﬁed protein
(Fig. 1A). A band at amolecular weight of approximately 24 kDawas
detected by Western blotting in extracts from both human frontal
cortex (Fig. 1A), human temporal cortex (Fig. 1B), and mouse frontal
cortex (Fig. 1A and B). To estimate protein levels of PSCA in cortical
tissue, the intensity of PSCA staining in cortical samples was
compared with that of recombinant PSCA with known concentra-
tions (Fig. 1A). Based on the standard curve, cortical tissue was
estimated to contain 0.3 and 0.5 ng/mg total protein for mouse and
human cortex, respectively. Co-incubation of the diluted PSCA
antiserum with the immunogen peptide prevented detection of
bands in both human and mouse cortical extracts (Fig. 1B).
Human temporal cortical tissue was fractionated into soluble
and membrane fractions by ultracentrifugation, and the resulting
fractions were subjected to Western blotting (Fig. 1C). PSCA was
detectable only in the soluble fraction. On the contrary, Lypd6 was
detected only in the membrane fraction. To validate the fraction-
ation method, we show that the two receptor units, b2 nAChR and
GluR2, were only present in the membrane fraction (Fig. 1C).
Afﬁnity puriﬁcation fromhuman temporal cortical homogenates
using magnetic beads coupled to recombinant human PSCAdemonstrated that PSCA was able to isolate the a4 nAChR subunit
(Fig. 1D). Afﬁnity puriﬁcation using uncoupled beads yielded no
isolation of a4 protein. By contrast, PSCA did not isolate the a7
nAChR subunit.
3.2. PSCA regulates nicotine-induced ERK phosphorylation in PC12
cells
Nicotine induces phosphorylation of the MAP kinase ERK in
PC12 cells (Fig. 2A). Recombinant human PSCA at 10 mM signiﬁ-
cantly inhibited nicotine-induced ERK phosphorylation by
approximately 30% in PC12 cells (p < 0.01), whereas 0.1 and 1 mM
had no signiﬁcant effects. PSCA alone did not affect basal levels of
ERK phosphorylation.
Stimulation of PC12 cells with PSCA (0.1, 1, and 10 mM) for
24 hours did not alter b2 protein levels (Fig. 2C). In addition, b2
mRNA levels in PC12 cells were unchanged, when silencing PSCA
levels using PSCA siRNA (Fig. 2E). The expression of PSCA was
reduced to approximately 40% by PSCA siRNA, when comparedwith
the expression in the presence of the negative control siRNA.
3.3. PSCA levels are increased in frontal cortex of AD patients
PSCA, Lypd6, and b2 protein levels were determined in human
postmortem cortical tissue from medial frontal gyrus using West-
ern blotting (Fig. 3). The levels of PSCA were increased by approx-
imately 70% in AD postmortem tissue comparedwith nondemented
(non-AD) control subjects (1.71  0.16, p ¼ 0.0025), whereas Lypd6
levels were unchanged (0.99  0.12, p ¼ 0.97). Levels of the b2
nAChR subunit were signiﬁcantly decreased in AD patients (0.66 
0.06, p ¼ 0.014).
Although AD subjects were noted to be slightly younger and
have slightly shorter postmortem delay than the non-AD control
subjects (see Table 1), we found no correlation between any of these
parameters or pH with protein levels of PSCA, Lypd6, and b2 nAChR
within the non-AD or AD groups.
Fig. 3. Prostate stem cell antigen (PSCA) protein levels are increased in medial frontal
gyrus in Alzheimer’s disease (AD). (A) Quantiﬁcation of PSCA and Lypd6 protein levels
as well as the b2 nAChR subunit in homogenized postmortem tissue of medial frontal
gyrus from AD patients and nondemented control subjects (non-AD). (B) Represen-
tative Western blot images of protein levels of non-AD and AD patients. Data are
normalized to actin levels, and the non-AD control group is set to 1. *p < 0.05 indicates
statistical difference from non-AD control subjects in multiple t tests with Holm-Sidak
multiple comparison test (n ¼ 7e8).
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Protein levels of PSCA, Lypd6, and the b2 nAChR subunit were
determined in frontal cortex and hippocampus from 6 to 19- to 21-
month-old 3Tg-AD mice and age-matched WT controls using
Western blotting (Fig. 4). In frontal cortex using two-way ANOVA
with age and genotype as independent variables, there was no
interaction of the variables, but a signiﬁcantmain effect of genotype
on PSCA and b2 nAChR levels in 3Tg-ADmice in the two age groups
(p < 0.01 and p < 0.05, respectively) compared with age-matched
WT mice (Fig. 4A), whereas there was no signiﬁcant main effect of
age. Subsequent unpaired t tests revealed that the effect of genotype
was driven primarily by the 6-month group, where 3Tg-AD mice
had signiﬁcantly enhanced PSCA (1.46  0.17, p ¼ 0.038) and sig-
niﬁcant lower b2nAChR levels (0.790.04,p<0.01) comparedwith
age-matched WT animals. PSCA and b2 nAChR levels in 19- to
21-month-old 3Tg-AD mice were not signiﬁcantly altered in un-
paired t tests (p ¼ 0.10 and p ¼ 0.23, respectively). In the hippo-
campus (Fig. 4A), therewere no signiﬁcantmain effects on PSCA and
b2 nAChR levels of genotype (p¼ 0.05 and p¼ 0.06, respectively) or
age (p¼ 0.19 and p¼ 0.35, respectively) in a two-wayANOVA. A two-
way ANOVA did not reveal any main effect of genotype or age in
Lypd6 levels in frontal cortex (p¼ 0.98 and p¼ 0.80, respectively) or
hippocampus (p ¼ 0.42 and p ¼ 0.94, respectively).Immunoﬂuorescence labeling was applied to sections of frontal
cortex and hippocampus in 21-month-old 3Tg-AD mice (Fig. 4C).
Frontal cortex displayed extracellular amyloid plaques as well as
intracellular deposits intermingled with phospho-tau-
immunoreactivity. In hippocampus, tau hyperphosphorylation
was present, and b-amyloidosis was more pronounced than in
frontal cortex (Fig. 4C). In 6-month-old 3Tg-AD mice, weak
intracellular Ab staining was displayed in both frontal cortex and
hippocampus. The staining of tissues comprising frontal cortex and
the hippocampus in age-matched WT mice revealed neither Ab-
immunoreactive senile plaques nor hyperphosphorylated tau (see
Supplementary Fig. 1).
3.5. PSCA levels are unchanged in frontal cortex of Tg2576 mice
In frontal cortex of Tg2576 mice, there were no signiﬁcant
changes in the levels of PSCA, Lypd6, and b2 nAChR subunit (Fig. 5)
compared with WT animals in unpaired t tests.
4. Discussion
Here, we show that the Lynx proteins PSCA and Lypd6 are pre-
sent in the human brain and that PSCA forms stable complexes with
the a4 nAChR subunit in the human temporal cortex and is able to
decrease nicotine-induced ERK phosphorylation in PC12 cells. We
further demonstrate that PSCA is increased in the frontal cortex of
AD patients as well as in 3Tg-AD mice. Because 3Tg-AD display
both age-dependent b-amyloidosis and tauopathy, this ﬁnding
suggests that increased levels of PSCA are linked to the patho-
physiology of AD.
PSCA was ﬁrst identiﬁed as a protein that was upregulated in
prostate cancer (Reiter et al., 1998). PSCAmRNA has previously been
demonstrated in the central nervous system of adult mouse and
chicken embryos (Hruska et al., 2009), and Lypd6 mRNA has been
found in human and mouse brain tissue (Darvas et al., 2009; Zhang
et al., 2010). We demonstrate that PSCA and Lypd6 proteins are
present in the human cortex. Because these Lynx proteins have
been associated with regulation of nAChR function in dissociated
neurons from chicken and mouse (Darvas et al., 2009; Hruska et al.,
2009), it is pertinent to study their function in the healthy and
diseased human brain.
Lynx proteins can exist as either glycosylphosphatidylinositol
(GPI)-anchored membrane proteins or soluble proteins (Adermann
et al., 1999; Bamezai, 2004). PSCA mRNA contains a GPI anchor
signaling site (Hruska et al., 2009; Reiter et al., 1998), and PSCA
protein is both secreted and cell-associated in PSCA-transfected
293T cells (Reiter et al., 1998). We detected native PSCA in the hu-
man brain exclusively as a soluble protein. Lypd6 was found to be
membrane-bound in the human cortex, which is in line with pre-
vious data on rat cortical tissue (Thomsen et al., 2013). Some GPI-
anchored proteins have been shown to have both membrane
bound and secreted forms, for example, CD59, another member of
the Lynx superfamily (Fritz and Lowe, 1996; Meri et al., 1996).
Soluble Lynx can diffuse to sites not available to the membrane-
bound GPI-anchored proteins. This may have an impact on how
Lynx proteins exert their function, for example, it was reported that
transgenic mice expressing secreted or full-length Lynx1, respec-
tively, show different effects in terms of motor learning (Miwa and
Walz, 2012).
We demonstrate that PSCA and the a4 nAChR subunit form
stable complexes in human cortex using afﬁnity puriﬁcation with
recombinant PSCA. We have recently shown that Lypd6 binds to
multiple nAChR subtypes in the human cortex (Thomsen et al.,
2013), and Lynx1 and Lynx2 have been shown to co-
immunoprecipitate with a7 and a4b2 nAChR subunits in
Fig. 4. Prostate stem cell antigen (PSCA) levels are increased in frontal cortex of 3Tg-AD mice. (A) Frontal cortex and hippocampus were dissected from triple transgenic (3Tg-AD)
mice and age-matched wild-type (WT) animals, homogenized, and protein analysis was performed using Western blotting. Data are normalized to actin levels, and the 6-month-old
WT group is set to 1 (n ¼ 7e8 per group). #p < 0.05, ##p < 0.01 indicates signiﬁcant main effect of genotype in two-way analysis of variance, *p < 0.05, **p < 0.01 indicates statistical
difference between 6-month-old 3Tg-AD and age-matched WT mice in unpaired t tests. (B) Representative Western blot images of protein levels in frontal cortex and hippo-
campus. (C) Immunoﬂuorescence labeling and confocal laser-scanning microscopy of neuropathologic alterations in the frontal cortex (I, III, V) and the hippocampal formation (II,
IV, VI) from a 21-month-old 3Tg-AD mouse. Biotinylated 4G8 visualized by green ﬂuorescent Cy2-streptavidin reveals both extracellular plaques and intracellular deposits in the
frontal cortex (I), whereas indirect immunolabeling with rabbit-anti-phospho-tau (Cy3, red) shows hyperphosphorylation in the same neocortical area (III). In the hippocampus,
several 4G8-immunopositive plaques are detectable (II), and abnormally phosphorylated tau is found in numerous cells including pyramidal neurons (IV). Merged pictures (V, VI)
indicate the allocation of the neuropathologic alterations. Scale bar ¼ 75 mm. (For interpretation of the references to color in this ﬁgure, the reader is referred to the Web version of
this article.)
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Tekinay et al., 2009). These studies suggest that there may be an
entire subfamily of Lynx proteins that bind to nAChRs in the brain.
It has previously been suggested that PSCA may be a negative
modulator of a7 nAChRs in chicken cililiary ganglion neurons
(Hruska et al., 2009). We did not detect co-puriﬁcation of the a7
nAChR subunit using PSCA afﬁnity puriﬁcation on human cortical
extracts. Possibly, the binding between PSCA and the a7 nAChR
subunit is not strong enough to be detected in our assay. Alterna-
tively, the binding of PSCA to nAChR subunits differs between
species, as it has been shown for Lynx1. Human Lynx1 competes
with binding of the a7 nAChR antagonist a-bungarotoxin to
acetylcholine-binding proteins and Torpedo nAChRs with an IC50 of
approximately 10 mM, suggesting that it binds to the orthosteric
site, whereas it does not compete with a-bungarotoxin binding to
human a7 nAChRs or with [3H]-epibatidine binding to human a4b2
nAChRs (Lyukmanova et al., 2011).
To investigate the potential effect of PSCA on nAChR function, we
determined the effect of PSCA on nicotine-induced phosphorylation
of the MAP kinase ERK. Activation of the intracellular MAPK/ERK
signaling pathway by phosphorylation plays a crucial role in the
formation of long-term potentiation and memory in hippocampus
(Adams and Sweatt, 2002). Nicotine has been suggested to induceERK phosphorylation in PC12 cells through a3b4 (Nakayama et al.,
2006) and to some extent a7 nAChRs (El Kouhen et al., 2009;
Gubbins et al., 2010). We show that 10 mM PSCA inhibits nicotine-
induced ERK phosphorylation in PC12 cells with no effect on
basal levels of ERK phosphorylation indicating that the inhibitory
effect is unique to nAChR signaling. The concentration of PSCA
corresponds to studies with Lynx1, which showed that 10 mM Lynx1
was able to inhibit ACh-induced currents in Xenopus oocytes
expressing human a7, a4b2, and a3b2, whereas 1 mM Lynx1was not
(Lyukmanova et al., 2011). These data suggest that PSCA could bind
to a7 nAChRs, although we were not able to detect it and possibly
also to a3b4 nAChRs. Thus, PSCA may function as a modulator of
nAChR function in the brain. That PSCA affects a signaling pathway
known to be important for neural plasticity and memory, makes it
an interesting target for future studies.
With the demonstration that PSCA and Lypd6 bind to and
modulate nAChRs, it is pertinent to investigate the function of PSCA
and Lypd6 in diseases, where nAChRs are dysregulated, such as AD.
nAChRs are important for normal cognitive function, and some
studies suggest a correlation between nAChR levels and cognitive
deﬁcits in AD (Nordberg et al., 1995; Okada et al., 2013; Perry et al.,
2000). Recent studies suggest that Lynx1, Lynx2, and Lypd6 are
involved in cognitive processes in rodents (Darvas et al., 2009;
Fig. 5. No changes in prostate stem cell antigen (PSCA) levels in frontal cortex of
Tg2576 mice over-expressing b-amyloid. (A) Frontal cortical extracts dissected from 15-
month-old male Tg2576 mice and age-matched wild-type (WT) controls were ho-
mogenized and followed by Western blotting for protein analysis. (B) Representative
images of Western blots. Data are normalized to actin levels, and the WT group is set to
1 (n ¼ 12e14 per group).
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disturbances seen in AD patients are caused by alterations in Lynx
protein function and/or expression is unknown. Here, we show that
the level of PSCA protein is increased in the frontal cortex of AD
patients. Combined with our ﬁnding that PSCA binds to the a4
nAChR subunit and inhibits nAChR signaling, increased PSCA levels
may decrease nAChR function in patients with AD. If PSCA is able to
inhibit the function of a4b2 nAChRs similar to Lynx1 (Ibanez-Tallon
et al., 2002), the dysfunction of the receptor may have negative
impact on the cognitive performance of the AD patients especially
on attention and executive function as has been described previ-
ously (Okada et al., 2013; Sarter et al., 2009). Lypd6 also binds to
nAChRs in human cortex (Thomsen et al., 2013) and is suggested as
a nAChR neuromodulator (Darvas et al., 2009; Thomsen et al.,
2013), but we found no change in Lypd6 levels in AD. Another
member of the Lynx superfamily CD59, which is involved in the
innate immune system as inhibitor of the membrane attack com-
plex (Davies et al., 1989), has been demonstrated to be down-
regulated in AD (Yang et al., 2000). Alterations of both PSCA and
CD59 in AD suggest that some Lynx proteins may be involved in the
disease.
Therefore, we asked whether altered protein levels of PSCA are
related to AD pathophysiology. We found increased PSCA protein
levels in frontal cortex of 3Tg-AD animals that overexpress Ab andhyperphosphorylated tau, the hallmarks of AD pathology. This in-
dicates that the combination of increased Ab and hyper-
phosphorylated tau are sufﬁcient to increase in PSCA protein and
suggest that the increase inPSCA levels found inADpatients is linked
to the pathophysiology of AD. PSCA levels were not altered in
transgenic Tg2576 mice that overexpress the Ab precursor APP and
display increased Ab levels (Hsiao et al., 1996). This suggests that
increased Ab levels are not sufﬁcient to increase PSCA levels. How-
ever, it should be noted that APP transgene animal models, such as
the Tg2576mice, showa slower accumulation of Abplaques than the
3Tg-ADmousemodel (reviewed by Lee and Han, 2013), so the lack
of effect in the model may reﬂect lower Ab load. Furthermore, the
progression and dynamics of AD pathology in 3Tg-AD mice are
rather similar to the pathogenesis in AD patients (Bilkei-Gorzo,
2014), where Ab deposition begins ﬁrst in cortical regions and
later in hippocampus, whereas tau pathology initiates in limbic re-
gions and then progresses to cortical regions (Oddo et al., 2003).
Here, we demonstrate by immunoﬂuorescence labeling of frontal
cortex and hippocampus from 3Tg-ADmice a pronounced AD-like
pathology in 21-month-old animals, whereas 6-month-old animals
are displaying intracellular Ab immunoreactivity but are devoid of
amyloid plaques or apparent tau pathology suggesting that the
changes in PSCA are not driven by tau pathology alone. Intracellular
immunoreactivity in the young animals could indicate cross-
reactivity of the applied antibody 4G8 for APP as previously re-
ported (Härtig et al., 2014;Winton et al., 2011). Becausewe show the
strongest increase of PSCA levels in 6-month-old 3Tg-ADmice, our
data indicate that the regulation of PSCA levels occurs before Ab
plaque and neuroﬁbrillary tangle formation, although this does not
preclude an involvement of soluble Ab forms in the regulation of
PSCA levels. Because bothAb andPSCAcanbind tonAChRs, theymay
share the same nAChR-binding site. However, it has been proposed
that binding of Ab to different nAChR subtypesmay involve different
binding sites (Nery et al., 2013). Our data suggest that increase in
PSCAmaybe aprecursor to stages of plaqueoverload in the3Tg-AD
mice, suggesting that the regulation of PSCA is an early event in the
progression of AD pathology in this animal model.
Because PSCA binds to a4-containing nAChRs, the altered
expression of nAChRs in AD could be a consequence of changes in
PSCA or vice versa. We demonstrate that b2 nAChR levels are
decreased in frontal cortex of AD patients and 3Tg-AD mice,
whereas they are not changed in Tg2576 animals and in the hip-
pocampus of 3Tg-AD mice, where we do not observe increased
PSCA levels. However, whenwe investigated PSCA in PC12 cells, we
did not ﬁnd alterations of b2 expression at both mRNA and protein
levels in the absence or presence of PSCA, respectively. It should be
noted that these ﬁndings do not exclude that PSCA is able to change
b2 expression in native tissue and/or under pathologic conditions.
The ﬁnding that PSCA and b2 nAChR levels are not increased in
hippocampus of the 3Tg-AD mice could be because of different
origin of the cholinergic input to frontal cortex and hippocampus,
respectively. Pathologic changes in the nuclei of the basal forebrain
may therefore inﬂuence the expression of PSCA and b2 nAChRs
more prominently in the frontal cortex. Regulation of frontal
cortical a4b2 nAChR expression in early-stage AD has previously
been demonstrated in humans, for example, a signiﬁcant reduction
in a4b2 binding in vivo in frontal cortex of patients with mild
cognitive impairment (Kendziorra et al., 2011) and early-stage AD,
which correlated with high [11C]-PiB uptake as a measure of amy-
loid deposits (Okada et al., 2013). In addition, [3H]-nicotine auto-
radiography in postmortem frontal cortical tissue showed a
signiﬁcantly reduced binding in AD patients (Marutle et al., 2013).
Given our data that PSCA binds to the a4 nAChR subunit, and the
fact that a4 and b2 nAChR subunits form heteromers, increased
PSCA expression may inﬂuence a4b2 nAChR levels in AD.
M.M. Jensen et al. / Neurobiology of Aging 36 (2015) 1629e1638 1637In summary, our ﬁndings have identiﬁed PSCA as a nAChR-
binding protein in the human brain. PSCA inhibits nAChR
signaling in vitro and is dysregulated in the frontal cortex of AD
patients as well as animal models with AD pathology. Therefore,
PSCA-nAChR interactions may affect cognitive function particularly
in the context of AD pathology.
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